The World Health Organization (WHO) is calling for urgent action in developing new vaccines for 17 deadly pathogens that cause widespread disease and death worldwide.
From HIV and malaria to tuberculosis and lesser-known threats, the WHO’s list prioritizes pathogens based on factors like disease burden, antimicrobial resistance, and socioeconomic impact.
Shifting Focus: Global Health Needs Over Profit
“We need to shift the focus from developing vaccines away from commercial returns towards regional and global health needs,” explained Mateusz Hasso-Agopsowicz, a WHO vaccine specialist.
This new initiative marks the first global effort to systematically prioritize vaccine research and development based on public health needs rather than market potential.
While the list reaffirms existing priorities like HIV, malaria, and tuberculosis – responsible for nearly 2.5 million deaths annually – it also highlights the urgency of tackling emerging threats.
Group A streptococcus, a bacterial infection causing severe illness and contributing to 280,000 deaths from rheumatic heart disease each year, is a prime example.
Another concerning pathogen is Klebsiella pneumoniae, a bacteria responsible for 40% of neonatal sepsis deaths in low-income countries.
The Impact of New Vaccines
“These vaccines would not only significantly reduce diseases that greatly impact communities today but also reduce the medical costs that families and health systems face,” stated Kate O’Brien, WHO vaccine chief.
Current vaccine development stages vary, with some, like those for HIV, Group A streptococcus, and hepatitis C virus, still in the research phase. Others, such as those for dengue and tuberculosis, are nearing regulatory approval and introduction.
The WHO emphasizes that prioritizing vaccine development based on health burden, not just commercial opportunities, is crucial to addressing global health inequities.
Support the WHO’s efforts to prioritize global health. Learn more about vaccine research and development initiatives at [insert WHO website link here].